By Rory Gallivan

LONDON--AstraZeneca PLC (AZN.LN) Friday announced positive results from a Phase III trial of its breast cancer treatment Lynparza.

Metastatic breast cancer patients treated with the drug "showed a statistically-significant and clinically-meaningful improvement" compared with patients who received chemotherapy, AstraZeneca said.

-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter: @RoryGallivan

(END) Dow Jones Newswires

February 17, 2017 02:30 ET (07:30 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Jan 2025 to Feb 2025 Click Here for more Astrazeneca Charts.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Feb 2024 to Feb 2025 Click Here for more Astrazeneca Charts.